Know Cancer

forgot password

Paclitaxel/Carboplatin (PC) Followed by Gefitinib or Paclitaxel/Carboplatin (PC) in Advanced Non-small Cell Lung Cancer (NSCLC): Randomized Phase II Study

Phase 2
18 Years
Not Enrolling
Non Small Cell Lung Cancer

Thank you

Trial Information

Paclitaxel/Carboplatin (PC) Followed by Gefitinib or Paclitaxel/Carboplatin (PC) in Advanced Non-small Cell Lung Cancer (NSCLC): Randomized Phase II Study

A randomized phase II trial that compares paclitaxel/carboplatin (PC) to PC chemotherapy
followed by gefitinib for 2 weeks in patients with NSCLC without EGFR mutations. While
previous studies with cytotoxic agents and gefitinib failed to show any benefit, we altered
the schedule of administration in hopes to gain synergy between agents.

Inclusion Criteria:

- More than 18 years of age

- Histologically documented non-small cell lung cancer with metastasis (Stage IV) or
locally advanced (Stage IIIB) with malignant effusion.

- At least 1 measurable lesion as defined by RECIST1.0. All target lesions must have a
unidirectional diameter of at least 1cm. Baseline measurements must be compared
within 4 weeks prior to enrollment.

- ECOG PS 0-2

- At least 1 week since the last radiotherapy. Patients must have recovered from all
acute toxicities from radiotherapy.

- Patients must have adequate hematologic, renal and liver function as defined by Hb >
9g/dL, neutrophils > 1000/mm3, platelets > 50,000/mm3, creatinine < 2mg/dL, and AST
(SGOT) and/or ALT (SGPT) < 5 x UNL (upper normal limit).

- Willingness and ability to comply with scheduled visits, treatment plans, laboratory
tests and other study procedures.

- Written and voluntary informed consent understood, signed and dated.

Exclusion Criteria:

- Patients with tumor harboring EGFR mutation.

- Prior systemic therapy for NSCLC

- Non-smoking patients with adenocarcinoma. But if those patients show wild type EGFR,
they are eligible to this study.

- Symptomatic brain metastasis. Brain metastases stable < 2 weeks before dosing or
requiring concurrent steroid treatment or with clinical symptoms.

- Major surgery within 3 weeks prior to study enrollment.

- Previous (less than 3 years ago) or current malignancies at sites other than
curatively treated in situ carcinoma of cervix, or basal or squamous cell carcinoma
of the skin.

- Severe medical illness or active infection that would impair the ability to receive

- Pregnancy or breast feeding.

Type of Study:


Study Design:

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Response Rate

Outcome Time Frame:

average 6 months

Safety Issue:


Principal Investigator

Sang-We Kim, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Asan Medical Center


Korea: Institutional Review Board

Study ID:

AMC 2009-0677



Start Date:

December 2009

Completion Date:

December 2012

Related Keywords:

  • Non Small Cell Lung Cancer
  • Carcinoma, Non-Small-Cell Lung
  • Lung Neoplasms